JAK2-V617F triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation

Blood

Volumn 113, Issue 8, 2009, Pages 1866-1868

  Kröger, Nicolaus ^a   Alchalby, Haefaa ^b   Klyuchnikov, Evgeny ^b   Badbaran, Anita ^b   Hildebrandt, York ^b   Ayuk, Francis ^b   Bacher, Ulrike ^b   Bock, Oliver ^b   Kvasnicka, Michael ^b   Fehse, Boris ^b   Zander, Axel ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2;

ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC STEM CELL TRANSPLANTATION; CD4+ T LYMPHOCYTE; DONOR LYMPHOCYTE INFUSION; GENETIC POLYMORPHISM; GRAFT VERSUS MYELOFIBROSIS; HUMAN; LETTER; MUTATION; MYELOFIBROSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION;

EID: 61949135475     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-11-190975     Document Type: Letter

References (9)

1. Mesa RA, Verstovsek S, Cervantes F, et al. International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res. 2007;31:737-740.
2. Kröger N, Mesa RA. Choosing between stem cell therapy and drugs in myelofi-brosis. Leukemia. 2008;474-486.
3. Kröger N, Zabelina T, Schieder H, et al. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Haematol. 2005;128:690-697.
4. Rondelli D, Barosi G, Bacigalupo A, et al. Myeloproliferative Diseases-Research Consortium. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelo-fibrosis with myeloid metaplasia. Blood. 2005;105:4115-4119.
5. Byrne JL, Beshti H, Clark D, et al. Induction of remission after donor leucocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: evidence for a "graft vs. myelofibrosis" effect. Br J Haematol. 2000;108:430-433.
6. Cervantes F, Rovira M, Urbano-Ispizua A, et al. Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect. Bone Marrow Transplant. 2000;26:697-699.
7. Benjamini O, Koren-Michowitz M, Amariglio N, et al. Relapse of postpolycythe-mia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation. Leukemia. 2008;22:1961-1963.
8. Tefferi A, Barosi G, Mesa RA, et al. IWG for Myelofibrosis Research and Treatment (IWG-MRT). International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood. 2006;108:1497-1503.
9. Kröger N, Badbaran A, Holler E, et al. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood. 2007;109:1316-1321.